Truncated l1 protein of human papillomavirus type 11

Patent metadata

Field	Value
Publication number	US-2018207257-A1
Application number	US-201815924511-A
Country	US
Kind code	A1
Filing date	Mar 19, 2018
Priority date	May 29, 2007
Publication date	Jul 26, 2018
Grant date	—

Abstract

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

First claim

1 - 13 . (canceled)

14 . A N-terminally truncated HPV11 L1 protein consisting of SEQ ID NO.: 2.

15 . A polynucleotide encoding the N-terminally truncated protein according to claim 14 .

16 . A vector comprising the polynucleotide according to claim 15 .

17 . A cell comprising the vector according to claim 16 .

18 . A composition comprising the N-terminally truncated HPV11 L1 protein according to claim 14 .

19 . A HPV 11 virus-like particle (VLP) comprising the N-terminally truncated HPV11 L1 protein according to claim 14 .

20 . A method for producing the N-terminally truncated HPV11 L1 protein according to claim 14 , comprising:
a) expressing a HPV L1 gene encoding the N-terminally truncated HPV L1 protein in an E. coli expression system; b) disrupting the E. coli , which has expressed the N-terminally truncated HPV L1 protein, in a solution at a salt concentration of from 100 mM to 600 mM, and isolating the supernatant; c) decreasing the salt concentration of the supernatant of b) to from 100 mM to 0, inclusive, by using water or a low salt solution, and collecting a precipitate; and d) redissolving the precipitation of c) in a solution at a salt concentration of from 150 mM to 2500 mM, adding a reductant to it, and then isolating the resultant solution, wherein the solution contains the N-terminally truncated HPV L1 protein with a purity of at least 50%.

21 . A vaccine for prevention of condyloma acuminatum or HPV infections, comprising HPV11 VLP according to claim 19 and carriers or excipients useful for vaccines.

22 . The vaccine for prevention of condyloma acuminatum or HPV infections according to claim 21 further comprising at least one HPV VLP selected from the group consisting of VLPs of HPV type 6, 16, 18, 31, 33, 45, 52, and 58.

23 . The vaccine for prevention of condyloma acuminatum or HPV infections according to claim 21 , further comprising a HPV 16 VLP comprising a protein having an amino acid sequence set forth in SEQ ID No: 8, and a HPV 18 VLP comprising a protein having an amino acid sequence set forth in SEQ ID No: 9.

24 . A method of claim 20 , further comprising:
e) further purifying the N-terminally truncated HPV 11 L1 protein with a purity of at least 50% by a chromatography; and f) removing the reductant from the HPV 11 L1 protein obtained in e).

25 . A method for producing a vaccine for prevention of condyloma acuminatum or HPV infections, comprising blending the VLP according to claim 19 , with carriers or excipients useful for vaccines.

26 . A method of claim 12 comprising blending the VLP according to claim 19 , and one or more VLPs selected from the group consisting of VLPs of HPV types 6, 16, 18, 31, 33, 45, 52, and 58, with carriers or excipients useful for vaccines.

Assignees

• Univ Xiamen
• Beijing Wantai Biological Pharmacy Entpr Co Ltd

Inventors

• Zhang Jun
• Wang Jin
• Yang Chunyan
• Gu Ying
• Li Shaowei
• Xia Ningshao

Classifications

• A61P31/20

  for DNA viruses · CPC title

• A61P15/00

  Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives · CPC title

• A61P17/12

  Keratolytics, e.g. wart or anti-corn preparations · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title

• C12N2710/20022

  New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title